Salivary gland squamous cell carcinoma
diseaseOn this page
Also known as epidermoid carcinoma of salivary glandepidermoid carcinoma of the salivary glandsaliva-secreting gland squamous cell carcinomasalivary gland epidermoid carcinomasalivary gland SCCsalivary gland squamous cell cancerSCC of salivary glandSCC of the salivary glandsquamous cell carcinoma of salivary glandsquamous cell carcinoma of the salivary gland
Summary
Salivary gland squamous cell carcinoma (MONDO:0044740) is a cancer and 27 clinical trials. Top therapeutic interventions include lapatinib, sorafenib, and cisplatin. A subtype of salivary gland carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 27
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | salivary gland squamous cell carcinoma |
| Mondo ID | MONDO:0044740 |
| EFO | EFO:1001967 |
| Orphanet | 500481 |
| NCIT | C7991 |
| UMLS | C0279697 |
| MedGen | 83545 |
| GARD | 0017929 |
| Anatomy (UBERON) | UBERON:0001044 |
| Is cancer (heuristic) | yes |
Also known as: epidermoid carcinoma of salivary gland · epidermoid carcinoma of the salivary gland · saliva-secreting gland squamous cell carcinoma · salivary gland epidermoid carcinoma · salivary gland SCC · salivary gland squamous cell cancer · salivary gland squamous cell carcinoma · SCC of salivary gland · SCC of the salivary gland · squamous cell carcinoma of salivary gland · squamous cell carcinoma of the salivary gland
Disease family
This is a subtype of salivary gland carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › salivary gland cancer › salivary gland carcinoma › salivary gland squamous cell carcinoma
Related subtypes (12): salivary gland adenoid cystic carcinoma, major salivary gland carcinoma, salivary gland basal cell adenocarcinoma, salivary gland carcinoma ex pleomorphic adenoma, salivary gland large cell carcinoma, salivary gland small cell carcinoma, salivary gland epithelial myoepithelial carcinoma, salivary gland mucoepidermoid carcinoma, salivary duct carcinoma, minor salivary gland carcinoma, salivary gland mucinous adenocarcinoma, mammary analog secretory carcinoma
Subtypes (2): parotid gland squamous cell carcinoma, salivary gland adenosquamous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 10 |
| PHASE1/PHASE2 | 4 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT00033618 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck |
| NCT00055770 | PHASE1/PHASE2 | COMPLETED | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer |
| NCT00055913 | PHASE1/PHASE2 | COMPLETED | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00096512 | PHASE2 | COMPLETED | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00098631 | PHASE2 | COMPLETED | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
| NCT00114283 | PHASE2 | COMPLETED | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
| NCT00458978 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer |
| NCT00507767 | PHASE2 | COMPLETED | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00939627 | PHASE2 | COMPLETED | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
| NCT01044433 | PHASE2 | COMPLETED | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck |
| NCT01256385 | PHASE2 | COMPLETED | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
| NCT01316757 | PHASE2 | COMPLETED | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| NCT01469429 | PHASE1/PHASE2 | COMPLETED | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. |
| NCT01816984 | PHASE1/PHASE2 | COMPLETED | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT00081211 | PHASE1 | TERMINATED | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck |
| NCT00906360 | PHASE1 | TERMINATED | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| NCT01249443 | PHASE1 | TERMINATED | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection |
| NCT01254617 | PHASE1 | COMPLETED | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer |
| NCT01283178 | PHASE1 | TERMINATED | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC |
| NCT01332279 | PHASE1 | WITHDRAWN | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy |
| NCT01334177 | PHASE1 | COMPLETED | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck |
| NCT01528137 | PHASE1 | TERMINATED | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer |
| NCT01847326 | PHASE1 | COMPLETED | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer |
| NCT02035527 | PHASE1 | COMPLETED | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT02245100 | Not specified | COMPLETED | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer |
| NCT03032250 | Not specified | COMPLETED | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LAPATINIB | 4 | 6 |
| SORAFENIB | 4 | 4 |
| CISPLATIN | 4 | 3 |
| DASATINIB ANHYDROUS | 4 | 2 |
| ERLOTINIB HYDROCHLORIDE | 4 | 2 |
| IXABEPILONE | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| TALACTOFERRIN ALFA | 3 | 1 |
| CHEMBL4583196 | 0 | 1 |